Back to search results

Semaglutide for Atrial Fibrillation and Weight Loss

This study is looking at how a medication called semaglutide, which helps with weight loss, might affect atrial fibrillation (AF), a type of irregular heartbeat. Researchers want to see if semaglutide, when added to standard AF treatment, can reduce how often AF occurs and its severity. You might be able to join if you are 18-75 years old, have a BMI (Body Mass Index) of 30 or higher (meaning you are overweight or have obesity), and have paroxysmal AF (comes and goes) or persistent AF (ongoing). The study will measure how long it takes for your first AF event to happen and changes in your AF burden (how much AF you experience) over 68 weeks. The current status of this study is unclear.

Study design
This is an interventional study with a planned enrollment of 200 participants. Participants will receive either semaglutide or a placebo (an inactive substance) via a pen-injector.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from baseline up to Week 68 to monitor for atrial fibrillation events and changes in AF burden.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06499857

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Recruiting
PHASE3Ages 18–75InterventionalTreatment
University of Chicago
~200 participants
Updated 2025-11-14 on ClinicalTrials.gov
What's tested:SemaglutidePlacebo

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first AF event detected by routine outpatient monitoring
Measured over Baseline to Week 68
+1 more outcome measured

Conditions

Overweight or Obesity
Atrial Fibrillation

Explore related trials

Atrial FibrillationObesity

NCT06499857

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Arizona College of Medicine- Phoenix

    Phoenix, Arizonastudy coordinator listed

    Not yet recruiting

  • University of Chicago

    Chicago, Illinoisstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Silvana Pannain, MD · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Silvana Pannain, MD
[email protected]
773-702-3275
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

2 blood sugars \<100 mg/dl- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 0-50 %
3 blood sugars 80-100 mg/dl- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 25-75%
3 blood sugars \<80 mg/dl \> 2 x week or severe hypoglycemia or symptomatic hypoglycemia- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 50-100 %

What this trial measures

  • Time to first AF event detected by routine outpatient monitoringBaseline to Week 68

    Defined by length of time detected by routine outpatient monitoring (Holter, mobile telemetry, or implantable loop recorder).

  • Change from baseline in AF burden detected by routine outpatient monitoring.Baseline to Week 68

    Defined as the percentage of time spent in atrial fibrillation as detected by routine outpatient monitoring (Holter, mobile telemetry, or implantable loop recorder).